COVID-19

Professor David Thomas said, “We are on the cusp of a new era in cancer care. It’s imperative to integrate this approach as mainstream care for all Australians.” 

“We have been advocating that NDAs [non-disclosure agreements] are not required for Implementation Group discussions and that there needs to be broad consultation and co-design of responses to the recommendations. Medicines Australia, just like consumer groups and the clinicians, will need to consult with everyone we represent," said chief executive Liz de Somer.

An implementation group is focused on the 'doing'. An advisory group is supporting the 'doing' process. This is not semantics because language matters. While the industry can be loose with its language, the government is not. The insertion of 'advisory' should be considered deliberate.

Pharmacy Guild of Australia President Professor Trent Twomey has welcomed the establishment of a new Masters of Pharmacy qualification.

Amgen has welcomed Health Minister Mark Butler's confirmation that the PBS listing of osteoporosis therapy EVENITY (romosozumab) has been expanded to a first-line setting for people who have had one fracture and are at very high risk of another.

Why should the community be denied broad expertise through implementation group members because of secrecy obligations? The use of secrecy obligations is a cancer in policy processes.

The Albanese Government's Health Technology Assessment Review implementation group faces one early test: Will its members accept the same operating framework that dominated the review's reference group?

Australian nuclear medicine company Telix Pharmaceuticals has expanded its theranostic pipeline with new assets targeting Fibroblast Activation Protein.

GBMA chair Professor Jane Halton AO PSM said economic modelling shows that each biosimilar molecule listed on the PBS could return up to $100 million to the health budget.

Healthcare providers Ramsay Health Care and Bupa Australia have announced a new program to support the development of the next generation of nurses.

Moderna has announced that Dr Felicia Pradera will succeed Dr Craig Rayner as the director of its Regional Research Centre for Respiratory Medicines and Tropical Diseases.

Today’s National Biotech and Medtech Development and Commercialisation Summit 2024 in Canberra will bring together more than 100 of Australia’s leading industry figures, policy experts, and innovators with the aim of shaping the future of the nation’s biotech and medtech sectors.